Spinal chemotherapy may stop brain damage from cancer treatment

NCT ID NCT06895473

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether injecting chemotherapy drugs (cytarabine, methotrexate, and hydrocortisone) into the spinal fluid can prevent severe brain side effects in people receiving CAR T-cell therapy for blood cancers. About 20-70% of CAR T patients develop neurotoxicity, which can cause confusion, seizures, or brain swelling. The study will enroll 26 adults and track how many develop serious brain symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cytarabine, methotrexate, and hydrocortisone injected into the spinal fluid
What this could lead to
If it works, this could make CAR T-cell therapy safer by preventing serious brain side effects, allowing more patients to benefit from this cancer treatment.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. The spinal injections themselves carry risks like headache or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.